HopeStage
Back to all studies
RecruitingNCT05529927

Extended-release dexamphetamine or placebo for cocaine use during opioid treatment

About this title

Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder

Read the official source — NCT05529927
Medication studyAges 18+NetherlandsAddiction
The study in practice

Understand this study

Who could participate?

Listed age limits: from 18 years.

Listed locations
The HagueSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: April 22, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
204
Sponsor
Parnassia Addiction Research Centre
Sponsor type
Research institute
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Netherlands
Age range
Over 18 Years
Official registry ID
NCT05529927
Official title
Show the full official title

Efficacy and Safety of 24 Weeks Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder With Comorbid Opioid Use Disorder - A Multicenter Randomized, Double-blind, Placebo-controlled Study

Recruitment & locations

Currently recruiting

The Hague

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Parnassia Addiction Research Centre, a research institute.

Does this study involve medication?

Yes. The study involves medication, including Sustained-release Dexamphetamine and Placebo.

Who can participate?

Listed age limits: from 18 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies